According to a media release issued earlier today in Australia, “a study led by Monash University researchers has found prostate cancer cells that survive androgen withdrawal treatment. Previously unidentified, these cells are potential targets for future treatments.” … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Risk | Tagged: ADT, androgen, cancer-repopulating, castration-tolerant, deprivation, refractory | 1 Comment »
For those who are interested in following the abiraterone story in more detail, Bernie Boyce has started a blog on his experiences in enrolling in and (he hopes) participating in the Phase III clinical trial of abiraterone under the supervision of Dr. de Bono at the Royal Marsden Hospital in the UK.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, Add new tag, cancer, hormone, prostate, refractory | 3 Comments »
Here’s a link to an excellent article on the “real” abiraterone story, written by journalist Robert Sandall, who has advanced prostate cancer himself. He has spoken to researcher Johann de Bono directly, and quotes him as follows:
Some parts of the press have hyped this drug way beyond what I said about it. … This is not a cure, let me correct that. I believe this drug definitely works — but it works much better with some patients than it does with others.
The “New” Prostate Cancer InfoLink is pleased to see Dr. de Bono confirm our earlier analysis of the situation.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, cancer, hormone, prostate, refractory | 4 Comments »
In additional news breaking today:
Filed under: Drugs in development, Management, Treatment | Tagged: cancer vaccine, Dendreon, ED, erectile dysfunction, hormone, NexMed, prostate, Provenge, refractory | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 